Lido Advisors
TEVA icon

Lido Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Lido Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$694K Buy
20,469
+272
+1% +$9.06K ﹤0.01% 1295
2026
Q1 		$608K Buy
20,197
+1,990
+11% +$64K ﹤0.01% 1192
2025
Q4 		$501K Buy
18,207
+67
+0.4% +$1.65K ﹤0.01% 1297
2025
Q3 		$366K Sell
18,140
-1,001
-5% -$17.6K ﹤0.01% 1390
2025
Q2 		$321K Buy
19,141
+43
+0.2% +$694 ﹤0.01% 1308
2025
Q1 		$294K Sell
19,098
-66
-0.3% -$1.18K ﹤0.01% 1223
2024
Q4 		$422K Sell
19,164
-42
-0.2% -$764 ﹤0.01% 1064
2024
Q3 		$346K Buy
19,206
+631
+3% +$11K ﹤0.01% 1101
2024
Q2 		$302K Sell
18,575
-669
-3% -$10.3K ﹤0.01% 1118
2024
Q1 		$272K Sell
19,244
-124
-0.6% -$1.56K ﹤0.01% 1140
2023
Q4 		$202K Buy
19,368
+2,556
+15% +$23.9K ﹤0.01% 1217
2023
Q3 		$171K Buy
16,812
+298
+2% +$2.77K ﹤0.01% 1094
2023
Q2 		$124K Sell
16,514
-262
-2% -$2.12K ﹤0.01% 1149
2023
Q1 		$148K Buy
+16,776
New +$166K ﹤0.01% 1050

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Lido Advisors's TEVA Position: Q2 2026 in Review

Lido Advisors increased its Teva Pharmaceuticals (TEVA) stake by 1.3% in Q2 2026, buying an estimated $9.06K and bringing the position to 20,469 shares worth $694K. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

Lido Advisors first reported a position in TEVA in Q1 2023 and has held it in 14 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Lido Advisors held 20,469 shares of Teva Pharmaceuticals worth $694K as of Q2 2026.
  • Lido Advisors bought 272 Teva Pharmaceuticals shares in Q2 2026, an estimated $9.06K.
  • Teva Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1295 holding.
  • Lido Advisors first reported a position in Teva Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.